Therefore, targeting EGFR and its downstream signaling, in combination with PD-1/PD-L1 ICIs, may hold the potential in restoring the T-lymphocyte killing capacity and improving the sensitivity to immunotherapy and targeted therapy in tumor patients (47, 64, 65). This evidence concerns the gene EGFR and neoplasm.